Fig.6 Application of Cas13b and Cas13d in vivo. (A) The scheme describes
the cross strategy of Cas13-Luciferase knock-down mice and luciferase
expressing transgenic mice. (B) Luciferase RNA expression of mouse
liver. The results are presented as mean ± SD. Data are analyzed by
unpaired Student’s t-test *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001. (C-D) Luciferase
images of male (B) and female (C) dTg (offspring of Cas13b-Luc gRNA KI
mating with Luciferase mouse) (n=5). (E) The scheme describes the
process of mcherry knock-down in mouse liver. (F-G) The mcherry RNA
expression in mouse liver. The results are presented as mean ± SD. Data
are analyzed by one-way ANOVA. ****P < 0.0001. (H)
Representative flow cytometry profiles and quantification of the
frequencies of mcherry positive cell population. (I) The results of
immunohistochemistry represent the expression of mcherry protein in
mouse liver (n=5). (J) The scheme describes the process of generation of
acute hepatic failure model and the gene knock-down strategy of
CRISPR/Cas13. (K) Hematoxylin-eosin staining results of mouse liver at
24 hours after injecting D-GalN/LPS (n=5), living or dead indicated the
animal state at the sampling time point. (L-M) NF-kB andTNFa RNA expression in mouse liver. The results are presented as
mean ± SD. Data are analyzed by one-way ANOVA. ****P < 0.0001.